Patents by Inventor Sahil S. Sangani

Sahil S. Sangani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND HYALURONIDASE VARIANTS AND FRAGMENTS THEREOF AND METHODS OF USE THEREOF
    Publication number: 20230365692
    Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof and a PH20 variant or fragment thereof. The invention further provides methods for treating various cancers with formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by subcutaneous administration.
    Type: Application
    Filed: September 23, 2021
    Publication date: November 16, 2023
    Applicant: MERCK SHARP & DOHME LLC
    Inventors: Yogita KRISHNAMACHARI, Sachin MITTAL, Sahil S. SANGANI, William P. FORREST, Jr., Yongchao SU, Xi ZHAO, Katelyn Jean SMITH
  • Stable Formulations of Programmed Death Receptor 1 (PD-1) Antibodies and Hyaluronidase Variants and Fragments Thereof and Methods of Use Thereof
    Publication number: 20220089738
    Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof and a PH20 variant or fragment thereof. The invention further provides methods for treating various cancers with formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by subcutaneous administration.
    Type: Application
    Filed: September 23, 2021
    Publication date: March 24, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Yogita Krishnamachari, Sachin Mittal, Sahil S. Sangani, William P. Forrest, JR., Yongchao Su, Xi Zhao
  • CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
    Publication number: 20220002410
    Abstract: The present invention provides co-formulations of anti-PD-1 antibodies and anti-LAG3 antibodies, and their use in treating various disorders.
    Type: Application
    Filed: November 6, 2019
    Publication date: January 6, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Valentyn Antochshuk, Preeti G. Desai, Yogita Krishnamachari, Sahil S. Sangani